Tocopherol-human serum albumin nanoparticles enhance lapatinib delivery and overcome doxorubicin resistance in breast cancer

References

• Pondé N, Brandão M, El-Hachem G, et al. Treatment of advanced HER2-positive breast cancer: 2018 and beyond. Cancer Treat Rev. W.B. Saunders Ltd; 2018;10–20. doi:10.1016/j.ctrv.2018.04.016
   PubMed Web of Science ®Google Scholar
• Breast Cancer [Internet]. [ Cited 2024 Mar 18]. Available from: https://www.bcrf.org/blog/her2-positive-breast-cancer-treatment-research/
   Google Scholar
• Bredin P, Walshe JM, Denduluri N. Systemic therapy for metastatic HER2-positive breast cancer. Semin Oncol. W.B. Saunders 2020;47(5):259–269.
   PubMed Web of Science ®Google Scholar
• Collins DM, Madden SF, Gaynor N, et al. Effects of HER family-targeting tyrosine kinase inhibitors on antibody-dependent cell-mediated cytotoxicity in HER2-expressing breast cancer. Clin Cancer Res. 2021;27:807–818. doi:10.1158/1078-0432.CCR-20-2007
   PubMed Web of Science ®Google Scholar
• Ma F, Ouyang Q, Li W, et al. Pyrotinib or Lapatinib combined with Capecitabine in HER2-positive metastatic breast cancer with prior taxanes, anthracyclines, and/ or trastuzumab: a randomized, phase II Study. J Clin Oncol. 2019;37(29). doi: 10.1200/JCO.19
   Web of Science ®Google Scholar
• D Johnston SR, Hegg R, Im S-A, et al. Phase III, randomized study of dual human epidermal growth factor receptor 2 (HER2) blockade with lapatinib plus trastuzumab in combination with an aromatase inhibitor in postmenopausal women with HER2-positive, hormone receptor-positive metastatic breast cancer: updated results of ALTERNATIVE. J Clin Oncol. 2020;38(1). doi:10.1200/JCO.20
   PubMedGoogle Scholar
• Bischoff J, Barinoff J, Mundhenke C, et al. A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab-pretreated patients with HER-2-positive metastatic breast cancer (E-VITA). Anticancer Drugs. 2019;30:394–401. doi:10.1097/CAD.0000000000000722
   PubMed Web of Science ®Google Scholar
• Kunte S, Abraham J, Montero AJ. Novel HER2–targeted therapies for HER2–positive metastatic breast cancer. Cancer. John Wiley and Sons Inc; 2020;4278–4288. doi:10.1002/cncr.33102
   PubMedGoogle Scholar
• Bonde GV, Yadav SK, Chauhan S, et al. Lapatinib nano-delivery systems: a promising future for breast cancer treatment. Expert Opin Drug Deliv. Taylor and Francis Ltd; 2018;495–507. doi:10.1080/17425247.2018.1449832
   PubMedGoogle Scholar
• Das S, Paul M, Ghosh B, et al. Synergistic anticancer response via docetaxel- and oleanolic acid-loaded albumin/poly(lactide) nanoparticles in triple-negative breast cancer. ACS Appl Nano Mater. 2023;6:19710–19726. doi:10.1021/acsanm.3c03499
   Web of Science ®Google Scholar
• Parodi A, Miao J, Soond SM, Rudzińska M, Zamyatnin AA. Albumin nanovectors in cancer therapy and imaging. Biomolecules. 2019;9(6):218. doi:10.3390/biom9060218
   PubMed Web of Science ®Google Scholar
• Itoo AM, Paul M, Ghosh B, Biswas S. Oxaliplatin delivery via chitosan/vitamin E conjugate micelles for improved efficacy and MDR-reversal in breast cancer. Carbohydr Polym. 2022;282. doi:10.1016/j.carbpol.2022.119108 .
   PubMed Web of Science ®Google Scholar
• Zeeshan F, Madheswaran T, Panneerselvam J, et al. Human serum albumin as multifunctional nanocarrier for cancer therapy. J Pharm Sci. Elsevier B.V. 2021;3111–3117. doi:10.1016/j.xphs.2021.05.001
   PubMed Web of Science ®Google Scholar
• Larsen MT, Kuhlmann M, Hvam ML, Howard KA. Albumin-based drug delivery: harnessing nature to cure disease. Mol Cell Ther. 2016;4(1). doi:10.1186/s40591-016-0048-8
   PubMedGoogle Scholar
• Kumari P, Ghosh B, Biswas S. Nanocarriers for cancer-targeted drug delivery. J Drug Target. Taylor and Francis Ltd; 2016;179–191. doi:10.3109/1061186X.2015.1051049
   PubMedGoogle Scholar
• Kumari P, Paul M, Bobde Y, et al. Albumin-based lipoprotein nanoparticles for improved delivery and anticancer activity of curcumin for cancer treatment. Nanomedicine. 2020;15:2851–2869. doi:10.2217/nnm-2020-0232
   PubMed Web of Science ®Google Scholar
• Abraham A, Kattoor AJ, Saldeen T, et al. Vitamin E and its anticancer effects. Crit Rev Food Sci Nutr. Taylor and Francis Inc.; 2019;2831–2838. doi:10.1080/10408398.2018.1474169
   PubMedGoogle Scholar
• Gorain B, Choudhury H, Pandey M, et al. Paclitaxel loaded vitamin E-TPGS nanoparticles for cancer therapy. Mater Sci Engin. 2018;91:868–880. doi:10.1016/j.msec.2018.05.054
   Google Scholar
• Duhem N, Danhier F, Préat V. Vitamin E-based nanomedicines for anti-cancer drug delivery. J Control Rel. 2014;182:33–44. doi:10.1016/j.jconrel.2014.03.009
   PubMed Web of Science ®Google Scholar
• Voigtlaender M, Schneider-Merck T, Trepel M. Lapatinib. Recent results in cancer research. Springer New York LLC. 2018;211:19–44. doi:10.1007/978-3-319-91442-8_2
   Google Scholar
• Mu Y, Sun D. Lapatinib, a dual inhibitor of epidermal growth factor receptor (EGFR) and HER-2, enhances radiosensitivity in mouse bladder tumor line-2 (MBT-2) cells in vitro and in vivo. Med Sci Monitor. 2018;24:5811–5819. doi:10.12659/MSM.909865
   PubMed Web of Science ®Google Scholar
• Kwon YS, Chun SY, Nam KS, et al. Lapatinib sensitizes quiescent MDA-MB-231 breast cancer cells to doxorubicin by inhibiting the expression of multidrug resistance-associated protein-1. Oncol Rep. 2015;34:884–890. doi:10.3892/or.2015.4047
   PubMed Web of Science ®Google Scholar
• Wan X, Zheng X, Pang X, et al. Lapatinib-loaded human serum albumin nanoparticles for the prevention and treatment of triple-negative breast cancer metastasis to the brain. Oncotarget. 2016;7(23). doi:10.18632/oncotarget.8697
   Google Scholar
• Wan X, Zheng X, Pang X, et al. The potential use of lapatinib-loaded human serum albumin nanoparticles in the treatment of triple-negative breast cancer. Rev Port Pneumol. 2002;8:131–138.
   Google Scholar
• Kumbham S, Paul M, Itoo A, et al. Oleanolic acid-conjugated human serum albumin nanoparticles encapsulating doxorubicin as synergistic combination chemotherapy in oropharyngeal carcinoma and melanoma. Int J Pharm. 2022;614:121479. doi:10.1016/j.ijpharm.2022.121479
   PubMedGoogle Scholar
• Paul M, Ghosh B, Biswas S, et al. Human serum albumin-oxaliplatin (Pt(IV)) prodrug nanoparticles with dual reduction sensitivity as effective nanomedicine for triple-negative breast cancer. Int J Biol Macromol. 2024;256: 128281.
   PubMed Web of Science ®Google Scholar
• Paramanantham A, Jung EJ, Kim HJ, et al. Doxorubicin-resistant tnbc cells exhibit rapid growth with cancer stem cell-like properties and emt phenotype, which can be transferred to parental cells through autocrine signaling. Int J Mol Sci. 2021;22(22). doi:10.3390/ijms222212438
   Web of Science ®Google Scholar
• Alkaraki A, Alshaer W, Wehaibi S, et al. Enhancing chemosensitivity of wild-type and drug-resistant MDA-MB-231 triple-negative breast cancer cell line to doxorubicin by silencing of STAT 3, Notch-1, and β-catenin genes. Breast Cancer. 2020;27:989–998. doi:10.1007/s12282-020-01098-9
   PubMed Web of Science ®Google Scholar
• Chakravarty G, Mathur A, Mallade P, et al. Nelfinavir targets multiple drug resistance mechanisms to increase the efficacy of doxorubicin in MCF-7/Dox breast cancer cells. Biochimie. 2016;124: 53–64.
   PubMed Web of Science ®Google Scholar
• Hekmat A, Salavati F, Hesami Tackallou S. The effects of paclitaxel in the combination of diamond nanoparticles on the structure of human serum albumin (HSA) and their antiproliferative role on MDA-MB-231 cells. Protein J. 2020;39:268–283. doi:10.1007/s10930-020-09882-4
   PubMed Web of Science ®Google Scholar